Related Experiment Videos
Olanzapine-induced rhabdomyolysis
C J Rosebraugh1, D A Flockhart, S U Yasuda
1Division of Clinical Pharmacology, Georgetown University Medical Center, Washington, DC 20007-2195, USA. Rosebra@aol.com
The Annals of Pharmacotherapy
|September 28, 2001
Summary
Olanzapine may cause rhabdomyolysis, a serious muscle condition. Lithium can also cause electrocardiogram changes mimicking heart damage. Always consider medication side effects in complex cases.
Area of Science:
- Pharmacology
- Toxicology
- Cardiology
Background:
- Antipsychotic medications like olanzapine are crucial for managing psychiatric conditions.
- Lithium is a common mood stabilizer with known cardiac effects.
- Rhabdomyolysis is a serious condition involving muscle breakdown.
Observation:
- A 13-year-old boy presented with severe weakness and electrocardiogram (ECG) abnormalities after initiating olanzapine and lithium therapy.
- The onset of weakness correlated with olanzapine administration.
- ECG changes were initially attributed to myocardial damage, not medication side effects.
Findings:
- The patient developed olanzapine-induced rhabdomyolysis, characterized by muscle pain and weakness.
- Lithium therapy contributed to pseudo-infarction ECG changes, mimicking cardiac injury.
- Adverse drug reactions were initially overlooked in the differential diagnosis.
Implications:
- This case highlights the potential for olanzapine to cause rhabdomyolysis.
- Lithium's ECG effects can be misinterpreted, necessitating careful evaluation.
- Clinicians must consider medication side effects in patients presenting with complex symptoms.